Ken Griffin
ANTX icon

Ken Griffin’s AN2 Therapeutics ANTX Stock Holding History

Ken Griffin’s Portfolio ANTX Stock Details ANTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$531K Buy
155,239
+39,703
+34% +$81.9K ﹤0.01% 9154
2025
Q4 		$132K Buy
115,536
+92,523
+402% +$108K ﹤0.01% 11427
2025
Q3 		$29.2K Buy
23,013
+10,516
+84% +$12K ﹤0.01% 12405
2025
Q2 		$13.2K Buy
+12,497
New +$14.9K ﹤0.01% 12173
2025
Q1 		– Sell
-67,994
Closed -$93.8K – 14412
2024
Q4 		$93.8K Buy
+67,994
New +$82.5K ﹤0.01% 11569
2024
Q3 		– Sell
-1,553,829
Closed -$3.34M – 14177
2024
Q2 		$3.34M Sell
1,553,829
-2,725
-0.2% -$6.49K ﹤0.01% 4390
2024
Q1 		$5.06M Sell
1,556,554
-288
-0% -$3.13K ﹤0.01% 3938
2023
Q4 		$31.9M Buy
1,556,842
+290
+0% +$4.85K 0.01% 1567
2023
Q3 		$25M Buy
1,556,552
+219,569
+16% +$2.49M 0.01% 1640
2023
Q2 		$11.4M Sell
1,336,983
-176
-0% -$1.26K ﹤0.01% 2511
2023
Q1 		$13.2M Buy
1,337,159
+176
+0% +$1.96K ﹤0.01% 2443
2022
Q4 		$12.7M Hold
1,336,983
– – ﹤0.01% 2489
2022
Q3 		$23.2M Buy
1,336,983
+3,167
+0.2% +$36.9K 0.01% 1730
2022
Q2 		$9.92M Sell
1,333,816
-86,035
-6% -$1.14M ﹤0.01% 2698
2022
Q1 		$20.6M Buy
+1,419,851
New +$21.5M ﹤0.01% 1955

Other funds holding ANTX

VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
SSC
Spruce Street Capital New York $416M AUM
AC
Almitas Capital Santa Monica, California $443M AUM 42.36% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
BCM
Boxer Capital Management San Diego, California $762M AUM 1,125.36% 1-Year Est. Return
SCM
Stonepine Capital Management Bend, Oregon $250M AUM 77.6% 1-Year Est. Return

Ken Griffin's ANTX Position: Q1 2026 in Review

Ken Griffin increased its AN2 Therapeutics (ANTX) stake by 34% in Q1 2026, buying an estimated $81.9K and bringing the position to 155,239 shares worth $531K. The position accounts for ﹤0.01% of the portfolio, ranked #9154.

Ken Griffin first reported a position in ANTX in Q1 2022 and has held it in 15 quarters since. The position peaked at $31.9M in Q4 2023. 52 funds tracked by Wall St. Rank hold ANTX as of Q1 2026.

  • Ken Griffin held 155,239 shares of AN2 Therapeutics worth $531K as of Q1 2026.
  • Ken Griffin bought 39,703 AN2 Therapeutics shares in Q1 2026, an estimated $81.9K.
  • AN2 Therapeutics made up ﹤0.01% of Ken Griffin's portfolio in Q1 2026, its #9154 holding.
  • Ken Griffin first reported a position in AN2 Therapeutics in Q1 2022 and has held it in 15 quarters since.
  • Ken Griffin's AN2 Therapeutics position peaked at $31.9M in Q4 2023.
  • 52 funds tracked by Wall St. Rank held AN2 Therapeutics as of Q1 2026.

Based on Citadel Advisors's 13F filing for Q1 2026, filed 15 May 2026.